Recorded Chinese product: 吡拉西坦氯化钠注射液吡拉西坦氯化钠注射液
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 广东利泰制药股份有限公司Chinese legal name: 广东利泰制药股份有限公司
主要成分Active Ingredients
- 吡拉西坦 采用钠作等渗调节剂Recorded Chinese composition: 吡拉西坦 采用钠作等渗调节剂
- 吡拉西坦Bila Xitan
- 采用钠作等渗调节剂Recorded Chinese composition: 采用钠作等渗调节剂
药物知识说明
吡拉西坦 采用钠作等渗调节剂是一种在国家药监局注册认定的药品。该药品含有吡拉西坦、吡拉西坦 采用钠作等渗调节剂、采用钠作等渗调节剂-6864b043等成分。
该药品关联的活性成分包括：吡拉西坦Bila Xitan、吡拉西坦 采用钠作等渗调节剂Recorded Chinese composition: 吡拉西坦 采用钠作等渗调节剂、采用钠作等渗调节剂Recorded Chinese composition: 采用钠作等渗调节剂。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：广东利泰制药股份有限公司Chinese legal name: 广东利泰制药股份有限公司。
您可以探索含有相同成分的其他药品：吡拉西坦-e6b3f02b成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 吡拉西坦氯化钠注射液) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 吡拉西坦Bila Xitan, 吡拉西坦 采用钠作等渗调节剂Recorded Chinese composition: Recorded Chinese name: 吡拉西坦 Recorded Chinese name: 采用钠作等渗调节剂, 采用钠作等渗调节剂Recorded Chinese composition: Recorded Chinese name: 采用钠作等渗调节剂.
Manufacturers recorded for this product: 广东利泰制药股份有限公司Chinese legal name: 广东利泰制药股份有限公司.
Explore other medicines containing the same ingredient: 吡拉西坦 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 吡拉西坦氯化钠注射液Recorded Chinese product: 吡拉西坦氯化钠注射液
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 250ml: 吡拉西坦8g与氯化钠2.25gRecorded Chinese composition: 250ml: 吡拉西坦8g与氯化钠2.25g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 广东利泰制药股份有限公司Chinese legal name: 广东利泰制药股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20113124
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20113124
Manufacturer
Chinese legal name: 广东利泰制药股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20113124
生产企业
广东利泰制药股份有限公司(国产)
适应症
本品适用于：|1.急、慢性脑血管病、脑外伤、各种中毒性脑病所致的记忆减退及轻、中度脑功能障碍。|2.治疗因脑外伤所致的颅内压增高症。
用法用量
1.用于改善脑代谢：|(1)肌肉注射一次1g，一日2～3次。|(2)静脉注射一次4g，一日一次。|(3)静脉滴注一次4～8g，一日一次(用5%或10%葡萄糖注射液或氯化钠注射稀释至250ml)。|2.用于降颅内压：静脉滴注，一次16～20g，5～10分钟内滴完，每6～8小时滴注一次，连续用药3～5天或遵医嘱。
不良反应
1.中枢神经系统不良反应包括神经质，易兴奋，头晕，头痛和睡眠障碍，但症状较轻,且与用药剂量无关。|2.轻度肝功能损害偶可见到，表现为轻度氨基转移酶升高，但与药物剂量无关。
禁忌
1.早产儿和新生儿忌用。|2.锥体外系疾病，Huntington舞蹈病者禁用，以免加重症状。
注意事项
1.肝肾功能不全者慎用，并应适当减少剂量。|2.与华法林合用时，应减少剂量，防止出血并发症的发生。|3.本品应用前请检查，如有结晶，可置温水中震荡待结晶完全溶解后再使用，并应使用有过滤器的输液器。
贮藏
遮光，密闭保存。
规格
250ml: 吡拉西坦8g与氯化钠2.25g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.